Correlation between MACE occurrence and FT3, cTnI, NT-proBNP in ACS patients with subclinical hypothyroidism
10.3760/cma.j.cn.115807-20230317-00083
- VernacularTitle:亚临床甲状腺功能衰退ACS患者发生MACE与FT3、cTnI、NT-proBNP关系探究
- Author:
Jingjing WANG
1
;
Haishan LI
Author Information
1. 合肥市第二人民医院急诊科，合肥 230000
- Keywords:
Acute coronary syndrome;
Free triiodothyronine;
Troponin;
Amino terminal pro brain natriuretic peptide;
Subclinical thyroid function decline
- From:
Chinese Journal of Endocrine Surgery
2023;17(5):608-612
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To predict the risk of major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS) patients with Subclinical thyroid function decline through exploration of free triiodothyronine (FT3), cardiac troponin I (cTnI), and N-terminal pro B-type natriuretic peptide (NT-proBNP) .Methods:A retrospective analysis was conducted on medical records of 125 ACS patients with Subclinical thyroid function decline to the Second People’s Hospital of Hefei City from Jan. 2020 to Mar. 2022. On the second day of hospitalization, fasting blood samples were collected from the patients. The levels of cTnI and NT-proBNP were measured using an electrochemiluminescence assay, while the level of FT3 was measured using a radioimmunoassay. The patients were followed up for 3 months to observe and record the occurrence of MACE. Based on the outcomes of MACE, the patients were divided into two groups: the adverse prognosis group and the good prognosis group. Logistic multivariate regression analysis was performed to identify the factors influencing the occurrence of MACE in ACS patients, and the predictive value of serum cTnI, NT-proBNP, and FT3 for MACE occurrence in ACS patients was evaluated.Results:Among the 125 ACS patients with Subclinical thyroid function decline, the incidence of MACE was 36 cases, with an incidence rate of 28.80%. Age ( OR=4.067, 95% CI: 1.856-10.231), hypertension ( OR=4.651, 95% CI: 1.942-9.779), diabetes ( OR=4.358, 95% CI: 1.887-10.051), coronary artery disease involving ≥3 vessels ( OR=4.047, 95% CI: 1.900-9.994), total cholesterol (TC) ( OR=4.100, 95% CI: 1.776-9.462), triglycerides (TG) ( OR=4.162, 95% CI: 1.558 - 11.114), low-density lipoprotein cholesterol (LDL-C) ( OR=3.428, 95% CI:1.642-8.743), serum cTnI ( OR=4.545, 95% CI: 1.987-10.394), and NT-proBNP ( OR=4.660, 95% CI: 2.045-10.617) were identified as risk factors for MACE occurrence ( P<0.05), while serum FT3 ( OR=0.275, 95% CI: 0.119-0.631) was considered a protective factor against MACE occurrence ( P<0.05). The individual and combined predictive values (area under the curve) of serum cTnI, NT-proBNP, and FT3 for MACE occurrence in ACS patients were 0.754, 0.738, 0.741, and 0.829, respectively. Conclusion:Serum cTnI, NT-proBNP, FT3 are closely related to the risk of MACE in patients with acute coronary syndrome with Subclinical thyroid function decline, and have high predic-tive power for the risk of mace.
